nach oben

Erschienen in:

05.06.2023 | Original Article

Cardiac sympathetic activity and relationship to cardiac events and left ventricular reverse remodeling in patients with non-ischemic dilated cardiomyopathy

verfasst von: Takashi Mizutani, Ryota Morimoto, Satoshi Isobe, Ryota Ito, Takashi Araki, Yuki Kimura, Shingo Kazama, Hideo Oishi, Tasuku Kuwayama, Hiroaki Hiraiwa, Toru Kondo, Takahiro Okumura, Toyoaki Murohara

Erschienen in: Annals of Nuclear Medicine | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Delayed heart-to-mediastinum ratio (HMR) has been associated with catecholamine levels and contractile reserve in dilated cardiomyopathy (DCM); however, there is scant evidence regarding the association between cardiac sympathetic activity and left ventricular reverse remodeling (LV-RR). We calculated the ¹²³I-metaiodobenzylguanidine (¹²³I-mIBG) HMR and washout rate (WR) in patients with DCM and investigated their associations with LV-RR.

Methods

From April 2003 to January 2020, in 120 patients with DCM who underwent ¹²³I-mIBG scintigraphy. 66 patients undergoing follow-up echo and taking a beta-blocker from baseline were examined the relationship between ¹²³I-mIBG and LV-RR. After that, this prognostic value for composite cardiac events was evaluated in the entire 120 patients.

Results

In LV-RR analysis, patients were 50.4 ± 12.2 years, with a mean left ventricular ejection fraction of 28.6%. Of 66 patients, 28 (42.4%) achieved LV-RR. Multiple logistic regression analysis of LV-RR revealed that not delayed HMR but the WR (cutoff value: 13.5%) was an independent predictor of LV-RR (odds ratio 6.514, p = 0.002). In the analysis for composite cardiac events, even though WR itself does not have the prognostic capacity, Kaplan–Meier survival curves divided by the cutoff value (delayed HMR = 2.0, WR = 13.5) showed that delayed HMR and WR values enabled the stratification of high-risk patients (log-rank p < 0.001).

Conclusions

The ¹²³I-mIBG WR was associated with the prevalence of LV-RR in patients taking 100% of beta-blockers and 98.5% of renin-angiotensin system inhibitors. Reflecting the contractile reserve, the combined assessment of the delayed HMR and WR could be used to further precisely stratify the patients with DCM.

Nur mit Berechtigung zugänglich

Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615–21.PubMedCrossRef

Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–23.PubMedCrossRef

Merlet P, Delforge J, Syrota A, Angevin E, Mazière B, Crouzel C, et al. Positron emission tomography with 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation. 1993;87:1169–78.PubMedCrossRef

Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, et al. Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts. N Engl J Med. 1982;307:205–11.PubMedCrossRef

Tripsokiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure. Physiology, pathophysiology and clinical implications. J Am Coll Cardiol. 2009;54:1747–62.

Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212–21.PubMedCrossRef

Nakajima K, Nakata T, Yamada T, Yamashina S, Momose M, Kasama S, et al. A prediction model for 5-year cardiac mortality in patients with chronic heart failure using ¹²³I-metaiodobenzylguanidine imaging. Eur J Nucl Med Mol Imaging. 2014;41:1673–82.PubMedPubMedCentralCrossRef

Momose M, Okayama D, Nagamatsu H, Kondo C, Hagiwara N, Sakai S. Long-term prognostic stratification by a combination of (123)I-metaiodobenzylguanidine scintigraphy and ejection fraction in dilated cardiomyopathy. Ann Nucl Med. 2011;25:419–24.PubMedCrossRef

Ohshima S, Isobe S, Izawa H, Nanasato M, Ando A, Yamada A, et al. Cardiac sympathetic dysfunction correlates with abnormal myocardial contractile reserve in dilated cardiomyopathy patients. J Am Coll Cardiol. 2005;6(46):2061–8.CrossRef

10.

Kobayashi M, Izawa H, Cheng XW, Asano H, Hirashiki A, Unno K, et al. Dobutamine stress testing as a diagnostic tool for evaluation of myocardial contractile reserve in asymptomatic or mildly symptomatic patients with dilated cardiomyopathy. JACC Cardiovasc Imaging. 2008;1:718–26.PubMedCrossRef

11.

Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Lenarda AD, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol. 2011;29(57):1468–76.CrossRef

12.

Verdonschot JAJ, Hazebroek MR, Wang P, Sanders-van Wijk S, Merken JJ, Adriaansen YA, et al. Clinical phenotype and genotype associations with improvement in left ventricular function in dilated cardiomyopathy. Circ Heart Fail. 2018;11:e005220.PubMedCrossRef

13.

Kimura Y, Okumura T, Morimoto R, Kazama S, Shibata N, Oishi H, et al. A clinical score for predicting left ventricular reverse remodelling in patients with dilated cardiomyopathy. ESC Heart Fail. 2021;8(2):1359–68.PubMedPubMedCentralCrossRef

14.

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39.e14.PubMedCrossRef

15.

Okuda K, Nakajima K, Hosoya T, Ishikawa T, Konishi T, Matsubara K, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-123 MIBG imaging. J Nucl Cardiol. 2011;18:82–9.PubMedCrossRef

16.

Nakajima K, Matsubara K, Ishikawa T, Motomura N, Maeda R, Akhter N, et al. Correction of iodine-123-labeled meta-iodobenzylguanidine uptake with multi-window methods for standardization of the heart-to-mediastinum ratio. J Nucl Cardiol. 2007;14:843–51.PubMedCrossRef

17.

Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol. 2014;21:970–8.PubMedPubMedCentralCrossRef

18.

Nakajima K, Verschure DO, Okuda K, Verberne HJ. Standardization of ¹²³I-meta-iodobenzylguanidine myocardial sympathetic activity imaging: phantom calibration and clinical applications. Clin Transl Imaging. 2017;5:255–63.PubMedPubMedCentralCrossRef

19.

Okuda K, Nakajima K, Kitamura C, Kirihara Y, Hashimoto M, Kinuya S. Calibrated scintigraphic imaging procedures improve quantitative assessment of the cardiac sympathetic nerve activity. Sci Rep. 2020;10:21834.PubMedPubMedCentralCrossRef

20.

Lee K, Daimon M, Kuwabara Y, Hasegawa R, Toyoda T, Sekine T, et al. Prediction of the response to beta-blocker therapy in patients with dilated cardiomyopathy: comparison of 123I-MIBG scintigraphy and low-dose dobutamine stress echocardiography. J Echocardiogr. 2009;7:74–9.PubMedCrossRef

21.

Morimoto R, Okumura T, Hirashiki A, Ishii H, Ichii T, Aoki S, et al. Myocardial contractile reserve predicts left ventricular reverse remodeling and cardiac events in dilated cardiomyopathy. J Cardiol. 2017;70:303–9.PubMedCrossRef

22.

Zhao C, Shuke N, Yamamoto W, Okizaki A, Sato J, Ishikawa Y, et al. Comparison of cardiac sympathetic nervous function with left ventricular function and perfusion in cardiomyopathies by (123)I-MIBG SPECT and (99m)Tc-tetrofosmin electrocardiographically gated SPECT. J Nucl Med. 2001;42:1017–24.PubMed

23.

Currie GM, Iqbal B, Wheat JM, Wang L, Trifunovic M, Jelinek HF, et al. Risk stratification in heart failure using ¹²³I-MIBG. J Nucl Med Technol. 2011;39:295–301.PubMedCrossRef

24.

Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;15(41):231–8.CrossRef

25.

Anastasiou-Nana MI, Terrovitis JV, Athanasoulis T, Karaloizos L, Geramoutsos A, Pappa L, et al. Prognostic value of iodine-123-metaiodobenzylguanidine myocardial uptake and heart rate variability in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2005;1(96):427–31.CrossRef

26.

Kuwabara Y, Tamaki N, Nakata T, Yamashina S, Yamazaki J. Determination of the survival rate in patients with congestive heart failure stratified by ¹²³I-MIBG imaging: a meta-analysis from the studies performed in Japan. Ann Nucl Med. 2011;25:101–7.PubMedCrossRef

27.

Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BLF. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147–59.PubMedCrossRef

28.

Cha YM, Chareonthaitawee P, Dong YX, Kemp BJ, Oh JK, Miyazaki C, et al. Cardiac sympathetic reserve and response to cardiac resynchronization therapy. Circ Heart Fail. 2011;4:339–44.PubMedCrossRef

29.

Kuramoto Y, Yamada T, Tamaki S, Okuyama Y, Morita T, Furukawa Y, et al. Usefulness of cardiac iodine-123 meta-iodobenzylguanidine imaging to improve prognostic power of Seattle heart failure model in patients with chronic heart failure. Am J Cardiol. 2011;15(107):1185–90.CrossRef

30.

Imamura T, Kinugawa K, Nitta D, Kinoshita O, Nawata K, Ono M. Preoperative iodine-123 meta-iodobenzylguanidine imaging is a novel predictor of left ventricular reverse remodeling during treatment with a left ventricular assist device. J Artif Organs. 2016;19:29–36.PubMedCrossRef

31.

Suwa M, Otake Y, Moriguchi A, Ito T, Hirota Y, Kawamura K, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J. 1997;133:353–8.PubMedCrossRef

32.

Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013;6:772–84.PubMedCrossRef

33.

Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol. 1999;33:759–66.PubMedCrossRef

34.

Hara Y, Hamada M, Ohtsuka T, Ogimoto A, Saeki H, Suzuki J, et al. Use of thallium-201 myocardial scintigraphy for the prediction of the response to beta-blocker therapy in patients with dilated cardiomyopathy. Circ J. 2002;66:1139–43.PubMedCrossRef

35.

Nishimura S, Izumi C, Himura Y, Kuroda M, Amano M, Harita T, et al. Very long-term follow-up data of non-ischemic idiopathic dilated cardiomyopathy after beta-blocker therapy: recurrence of left ventricular dysfunction and predictive value of ¹²³I-metaiodobenzylguanidine scintigraphy. Heart Vessels. 2019;34:259–67.PubMedCrossRef

36.

Fujimoto S, Inoue A, Hisatake S, Yamashina S, Yamashina H, Nakano H, et al. Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of β-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis. Eur J Nucl Med Mol Imaging. 2004;31:1356–61.PubMedCrossRef

37.

Böhm M, Rosée KL, Schwinger RHG, Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol. 1995;25:146–53.PubMedCrossRef

38.

Verschure DO, Poel E, Vincentis GD, Frantellizzi V, Nakajima K, Gheysens O, et al. The relation between cardiac 123I-mIBG scintigraphy and functional response 1 year after CRT implantation. Eur Heart J Cardiovasc Imaging. 2021;22:49–57.PubMedCrossRef

39.

Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol. 2009;53:426–35.PubMedCrossRef

40.

Fukuoka S, Hayashida K, Hirose Y, Shimotsu Y, Ishida Y, Kakuchi H, et al. Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of blocker therapy in patients with dilated cardiomyopathy. Eur J Nucl Med. 1997;24:523–9.PubMed

41.

Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy—clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J. 2001;141:645–52.PubMedCrossRef

42.

Fukuda K, Hasegawa S, Kawamura T, Waratani N, Hirata K, Higashimori A, et al. Changes in cardiac sympathetic nerve activity on 123 I-metaiodobenzylguanidine scintigraphy after MitraClip therapy. ESC Heart Fail. 2021;8:1590–5.PubMedPubMedCentralCrossRef

43.

Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, et al. Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J. 2007;28:989–95.PubMedCrossRef

44.

Marume K, Noguchi T, Tateishi E, Morita Y, Kamakura T, Ishibashi K, et al. Mortality and sudden cardiac death risk stratification using the noninvasive combination of wide QRS duration and late gadolinium enhancement in idiopathic dilated cardiomyopathy. Circ Arrhythm Electrophysiol. 2018;11(4):e006233.PubMedCrossRef

45.

Konishi S, Ohtani T, Mizuno H, Sera F, Nakamoto K, Chimura M. Simple electrocardiographic score can predict left ventricular reverse remodeling in patients with non-ischemic cardiomyopathy. Circ Rep. 2019;1(4):171–8.PubMedPubMedCentralCrossRef

46.

Kasama S, Toyama T, Kaneko Y, Iwasaki T, Sumino H, Kumakura H, et al. Relationship between late ventricular potentials and myocardial 123I-metaiodobenzylguanidine scintigraphy in patients with dilated cardiomyopathy with mild to moderate heart failure: results of a prospective study of sudden death events. Eur J Nucl Med Mol Imaging. 2012;39:1056–64.PubMedCrossRef

47.

Chimura M, Yamada S, Taniguchi Y, Yasaka Y, Kawai H. Late gadolinium enhancement on cardiac magnetic resonance combined with 123I-metaiodobenzylguanidine scintigraphy strongly predicts long-term clinical outcome in patients with dilated cardiomyopathy. PLoS One. 2019;20(14):e0217865.CrossRef

Titel: Cardiac sympathetic activity and relationship to cardiac events and left ventricular reverse remodeling in patients with non-ischemic dilated cardiomyopathy
verfasst von: Takashi Mizutani
Ryota Morimoto
Satoshi Isobe
Ryota Ito
Takashi Araki
Yuki Kimura
Shingo Kazama
Hideo Oishi
Tasuku Kuwayama
Hiroaki Hiraiwa
Toru Kondo
Takahiro Okumura
Toyoaki Murohara
Publikationsdatum: 05.06.2023
Verlag: Springer Nature Singapore
Erschienen in: Annals of Nuclear Medicine / Ausgabe 8/2023
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-023-01838-9

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Cardiac sympathetic activity and relationship to cardiac events and left ventricular reverse remodeling in patients with non-ischemic dilated cardiomyopathy

Abstract

Background

Methods

Results

Conclusions

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2023

Advances in the molecular imaging of primary aldosteronism

What radiolabeled FAPI pet can add in breast cancer? A systematic review from literature

Effects of apitherapy against salivary gland disorder after radioactive iodine therapy for differentiated thyroid cancer

Usefulness of preset count acquisition in pediatric 99m Tc-DMSA planar imaging